The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1543
ISSUE1543
March 26, 2018
Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy
March 26, 2018 (Issue: 1543)
The FDA has approved voretigene neparvovec-rzyl
intraocular suspension (Luxturna – Spark), an
adeno-associated virus vector-based gene therapy,
for treatment of confirmed biallelic RPE65 mutation-associated
retinal dystrophy in patients who...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.